Peter Hammerman
Stealthy Third Rock startup poaches oncology exec from Novartis — just days after his boss jumped ship
Novartis’ oncology research unit has lost another top exec to biotech’s lure.
Peter Hammerman, the global head of oncology translational research at NIBR, revealed his …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.